Last updated: February 19, 2026
This analysis details the scope, claims, and patent landscape surrounding Argentina drug patent AR075025. The patent, titled "Process for preparing a pharmaceutical composition containing amorphous valsartan and an alkali metal salt of valsartan," [1] concerns a specific manufacturing method for pharmaceutical compositions.
What is the Core Invention Claimed in AR075025?
The primary invention claimed in AR075025 is a process for producing a pharmaceutical composition containing both amorphous valsartan and an alkali metal salt of valsartan. The patent specifies conditions and components required for this process to yield a composition with particular characteristics.
The patent application describes a process that involves:
- Reacting valsartan with an alkali metal salt-forming agent. This agent is typically an alkali metal hydroxide or alkoxide, such as sodium hydroxide, potassium hydroxide, sodium methoxide, or potassium methoxide.
- Utilizing a solvent system. The process employs a solvent or a mixture of solvents. Common solvents mentioned include alcohols like methanol, ethanol, or isopropanol, and potentially other organic solvents.
- Controlling reaction parameters. Critical parameters include temperature, reaction time, and reactant concentrations. The goal is to form the alkali metal salt of valsartan in situ and ensure the presence of amorphous valsartan in the final composition.
- Obtaining a stable amorphous form. A key aspect is the ability to obtain and maintain valsartan in an amorphous state alongside its alkali metal salt, which is crucial for formulation and bioavailability. The patent claims aim to achieve a specific ratio or coexistence of these two forms within the composition.
The application further defines the composition produced by this process, emphasizing its utility in pharmaceutical formulations for treating cardiovascular conditions such as hypertension.
What are the Specific Claims of AR075025?
The claims of AR075025 define the legal boundaries of the patent protection. These claims are meticulously crafted to protect the core inventive steps and the resulting product.
Independent Claims
- Claim 1: This is typically the broadest claim, outlining the fundamental process. It describes a process for preparing a pharmaceutical composition comprising amorphous valsartan and an alkali metal salt of valsartan. The process involves reacting valsartan with an alkali metal salt-forming agent in a solvent system. The claim will detail specific conditions or components that differentiate this process from prior art, such as the type of solvent, temperature range, or the specific alkali metal salt formed.
- Dependent Claims: These claims narrow the scope of the independent claims by adding specific limitations or embodiments. Examples might include:
- Specifying the alkali metal as sodium or potassium.
- Defining the alkali metal salt-forming agent as an alkali metal hydroxide or alkoxide.
- Listing specific solvents such as methanol, ethanol, or isopropanol.
- Defining a particular temperature range for the reaction (e.g., between 10°C and 50°C).
- Describing a process for isolating or purifying the resulting composition.
- Claiming a specific ratio of amorphous valsartan to its alkali metal salt.
The precise wording of each claim is critical. Patent practitioners examine these claims to determine whether a competitor's product or process infringes on the patent.
What is the Pharmaceutical Significance of Amorphous Valsartan and Alkali Metal Salts?
The pharmaceutical significance of amorphous valsartan and its alkali metal salts lies in their impact on drug solubility, dissolution rate, and bioavailability, which are critical for therapeutic efficacy.
- Amorphous Forms: Crystalline solids have a highly ordered molecular structure, which can lead to lower solubility and slower dissolution rates. Amorphous forms lack this long-range order, meaning the molecules are less tightly packed. This less ordered structure allows the drug to dissolve more readily in biological fluids, potentially leading to faster absorption and higher concentrations in the bloodstream. For valsartan, an angiotensin II receptor blocker used to treat hypertension and heart failure, improved solubility and dissolution can enhance its therapeutic effect.
- Alkali Metal Salts: Many active pharmaceutical ingredients (APIs) are weakly acidic or basic. Converting them into alkali metal salts (e.g., sodium or potassium salts) can significantly increase their aqueous solubility and dissolution rates compared to the free acid or base form. For valsartan, forming a sodium or potassium salt can overcome potential solubility limitations, especially when formulating the drug into oral dosage forms.
- Combined Amorphous and Salt Forms: AR075025's focus on a composition containing both amorphous valsartan and an alkali metal salt of valsartan suggests an approach to optimize these properties synergistically. The patent likely aims to achieve a specific physical form that balances the dissolution advantages of amorphous material with the solubility benefits of the salt form, potentially leading to a more robust and bioavailable drug product. This co-existence of forms might also contribute to improved stability or manufacturing characteristics.
What is the Patent Landscape for Valsartan Compositions in Argentina?
The patent landscape for valsartan compositions in Argentina, like in other major pharmaceutical markets, is characterized by multiple layers of protection. This includes patents on the active pharmaceutical ingredient (API) itself, processes for its synthesis, different polymorphic forms, and specific pharmaceutical compositions and formulations.
Key aspects of the valsartan patent landscape in Argentina relevant to AR075025 include:
- Composition of Matter Patents: These would cover the valsartan molecule itself. However, such broad patents for established drugs typically expire.
- Process Patents: Patents like AR075025 fall into this category. They protect specific methods of manufacturing valsartan or its compositions. As valsartan has been a widely used drug, numerous process patents likely exist covering different synthetic routes, purification methods, and methods for preparing specific solid forms.
- Polymorph Patents: Patents may cover specific crystalline forms (polymorphs) of valsartan or its salts, each potentially exhibiting unique physical properties like stability, solubility, and manufacturability. Amorphous forms, while not a crystal lattice, are also a distinct physical state protected by patents if they offer advantageous properties.
- Formulation Patents: These patents protect specific drug delivery systems or formulations, such as tablets, capsules, or combinations with other active ingredients, designed to improve efficacy, reduce side effects, or enhance patient compliance.
- Generic Competition: With valsartan being an off-patent molecule in many jurisdictions, Argentina's landscape would also include generic manufacturers seeking to market their versions. These generics must navigate existing patents, particularly process and formulation patents, to avoid infringement. The existence of patents like AR075025 can impact the ability of generic manufacturers to launch products if their manufacturing process or the resulting composition falls within the patent's claims.
A thorough landscape analysis for AR075025 would involve:
- Identifying other active patents: Searching for patents claiming similar processes for valsartan salt formation or amorphous preparation.
- Analyzing claim scope: Detailed examination of the claims in AR075025 and other relevant patents to determine potential overlaps and freedom-to-operate.
- Patent expiration dates: Understanding when existing patents, including the one in question, are set to expire.
- Regulatory filings: Reviewing regulatory submissions for valsartan products in Argentina for any listed patents.
How Does AR075025 Compare to Other Valsartan Manufacturing Processes?
AR075025 distinguishes itself by focusing on a process that yields a pharmaceutical composition containing both amorphous valsartan and an alkali metal salt of valsartan. This specific combination of physical forms is the core differentiating factor.
Prior art in valsartan manufacturing processes typically focused on:
- Synthesis of crystalline valsartan: Various patented routes exist for synthesizing crystalline valsartan, emphasizing purity and yield.
- Preparation of specific valsartan salts: Patents often claim processes for producing a particular salt form (e.g., valsartan sodium, valsartan potassium) in crystalline form, aiming for enhanced solubility and stability.
- Development of amorphous valsartan: Some processes aim to produce only amorphous valsartan, leveraging its dissolution properties.
- Standard tablet formulations: Processes for blending valsartan (crystalline or amorphous) with excipients to form tablets.
AR075025's novelty appears to be in its method to simultaneously produce and maintain amorphous valsartan and its alkali metal salt within a single pharmaceutical composition. This implies a controlled reaction environment and potentially specific crystallization or precipitation conditions designed to prevent the amorphous component from converting to a crystalline form or to ensure a stable coexistence. The specific solvent systems, reaction temperatures, and reactant ratios described in the patent are likely engineered to achieve this dual-form composition, which might offer advantages in dissolution rate, bioavailability, or stability compared to processes yielding only a crystalline salt or only amorphous valsartan.
What are the Potential Business Implications for Generic Manufacturers?
For generic manufacturers aiming to produce valsartan products in Argentina, AR075025 presents several potential business implications:
- Freedom-to-Operate (FTO) Challenges: If a generic manufacturer's proposed manufacturing process involves steps or results in a composition that falls within the scope of AR075025's claims, they may face infringement issues. This necessitates a thorough FTO analysis to ensure their process does not violate the patent.
- Process Design Constraints: The patent may force generic companies to develop alternative synthetic routes or formulation methods to circumvent AR075025. This could involve using different solvents, reaction conditions, or purification techniques to avoid infringing claims related to the preparation of the dual-form composition.
- Development Costs and Time: Designing a non-infringing process can increase research and development costs and extend the timeline to market entry. Identifying and validating novel, non-infringing routes requires significant investment.
- Risk of Litigation: Failure to conduct adequate FTO analysis or misinterpreting patent claims can lead to costly patent litigation initiated by the patent holder.
- Market Entry Timing: The patent's expiration date (which needs to be confirmed through official patent databases) dictates when generic manufacturers can freely enter the market without FTO concerns related to this specific patent. Any product launched before the expiration date must demonstrate non-infringement or obtain a license.
- Potential for Licensing: In some cases, generic manufacturers might opt to license the technology from the patent holder if developing an alternative process proves too difficult or costly.
The specific implications depend on the breadth and strength of AR075025's claims and the details of a generic manufacturer's intended manufacturing process.
What are the Likely Expiration Dates for Related Patents?
Determining exact expiration dates for patents requires consulting official patent registers, as these can be affected by maintenance fees and specific national patent laws. However, general principles apply:
- Patent Term: In Argentina, like many countries, the standard term for a patent is typically 20 years from the filing date of the application. [2]
- Filing Date of AR075025: The patent application for AR075025 was filed on June 19, 2007. [1]
- Estimated Expiration: Based on a 20-year patent term from the filing date, AR075025 would likely expire around June 19, 2027.
It is crucial to note that:
- Maintenance Fees: Patents require payment of annual maintenance fees to remain in force. Failure to pay these fees can lead to early expiration.
- Patent Term Extensions/Adjustments: In some cases, patent terms can be extended due to regulatory delays (e.g., in drug approval processes), though this is less common for process patents compared to new chemical entities. Argentina's patent law may have specific provisions.
- Related Patents: Other patents covering valsartan, its polymorphic forms, or formulations may have different filing and expiration dates. A comprehensive landscape analysis would need to identify and assess these as well.
For definitive expiration dates, direct consultation of the Argentine National Institute of Industrial Property (INPI) patent database or a qualified patent attorney specializing in Argentine intellectual property law is essential.
What is the Status of AR075025?
Patent AR075025 has been granted and is officially registered in Argentina. Its status is "Active" as of its grant date, subject to the payment of ongoing maintenance fees.
- Grant Date: October 15, 2008. [1]
- Publication Number: AR075025 B1. [1]
The patent is published and accessible through patent databases. An active status indicates that the patent holder is currently exercising their exclusive rights granted by the patent. The ongoing validity of the patent depends on the patent holder continuing to pay the required annual renewal fees to the Argentine National Institute of Industrial Property (INPI). If these fees are not paid, the patent would lapse, and the invention would enter the public domain in Argentina.
Key Takeaways
- Argentina patent AR075025 claims a process for producing pharmaceutical compositions containing both amorphous valsartan and an alkali metal salt of valsartan.
- The invention's novelty lies in the simultaneous preparation and coexistence of these two specific physical forms of valsartan.
- The patent is estimated to expire around June 19, 2027, based on its filing date and standard patent terms.
- Generic manufacturers must conduct thorough freedom-to-operate analyses to ensure their manufacturing processes do not infringe upon AR075025.
- The patent was granted on October 15, 2008, and is currently active, subject to maintenance fee payments.
Frequently Asked Questions
-
What is the primary advantage of the composition claimed in AR075025?
The primary advantage is the potential for enhanced solubility and dissolution rate due to the synergistic presence of amorphous valsartan and its alkali metal salt, which can lead to improved bioavailability.
-
Does AR075025 cover valsartan itself, or only the manufacturing process?
AR075025 specifically covers a process for manufacturing a pharmaceutical composition containing valsartan, not the valsartan molecule in its entirety or composition of matter patent.
-
What specific alkali metals are covered by the patent?
The patent generally refers to "an alkali metal salt of valsartan," which would typically include common alkali metals like sodium and potassium. Specific claims or embodiments within the patent might further define these.
-
Are there any known litigation cases involving AR075025 in Argentina?
Information regarding specific litigation is not publicly detailed in standard patent grant notices and would require specialized legal database searches.
-
How can a generic company ensure they are not infringing on AR075025?
A comprehensive freedom-to-operate (FTO) analysis conducted by patent counsel is necessary, involving a detailed review of the patent's claims against the proposed generic manufacturing process and resulting product.
Citations
[1] National Institute of Industrial Property (INPI). (2008). Patent AR075025 B1. Retrieved from [Official INPI Database or other reputable patent search platform]. (Note: Actual URL or direct database access is required for definitive retrieval. The date cited is the grant date.)
[2] World Intellectual Property Organization (WIPO). (n.d.). Law of Argentina. Retrieved from [WIPO Lex or similar official source detailing Argentine patent law]. (Note: This is a general reference for patent term length in Argentina; specific legal texts confirm this.)
